Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Deepak N. Amarapurkar"'
Autor:
Vinod H. Gupta, Meenakshi Singh, Deepak N. Amarapurkar, Preetha Sasi, Jyotsna M. Joshi, Rajiv Baijal, Praveen Kumar H.R., Anjali D. Amarapurkar, Kalpana Joshi, Pramod P. Wangikar
Publikováno v:
Annals of Hepatology, Vol 12, Iss 6, Pp 959-965 (2013)
Background. The first line anti-tubercular (anti-TB) treatment normally involves isoniazid, rifampicin, pyrazinamide, and ethambutol. Clearance of these drugs depends on the activity of several enzymes such as N-acetyl transferase 2, cytochrome P450
Externí odkaz:
https://doaj.org/article/6ac84f2137484ae291b3225b643e5233
Publikováno v:
Annals of Hepatology, Vol 7, Iss 2, Pp 148-151 (2008)
Background: Diabetes mellitus (DM) is recently identified risk factor for development and progression of chronic liver disease as well as hepatocellular carcinoma (HCC). We planned a prospective analysis to identify impact of DM in Indian patients wi
Externí odkaz:
https://doaj.org/article/cac8e9317b9b48458aa8412c3e1ceb26
Publikováno v:
Annals of Hepatology, Vol 6, Iss 3, Pp 170-173 (2007)
Background: Chronic liver disease is characterized by inflammation and fibrosis. As a consequence angiogenesis leading to new vasculature may have prognostic value in disease progression. Interfering with angiogenesis may be a potential target to avo
Externí odkaz:
https://doaj.org/article/4ecbb63e867e4e28af320d272252eab5
Publikováno v:
Annals of Hepatology, Vol 5, Iss 2, Pp 103-108 (2006)
Background: In refractory ascites/hydrothorax (RA), uncovered transjugular intrahepatic portosystemic shunt (TIPS) is shown to be superior to large-volume therapeutic paracentesis (LVP) for long-term control of ascites, but at a cost of increased ris
Externí odkaz:
https://doaj.org/article/c9ee08a9084c45c09ecd3d95975b0945
Autor:
Deepak N. Amarapurkar, Nikhil D. Patel
Publikováno v:
Annals of Hepatology, Vol 4, Iss 1, Pp 56-59 (2005)
Introduction: Treatment strategies for chronic hepatitis B (CHB) using either interferon or Lamivudine can achieve sustained response in 30-40 % in HBeAg positive CHB. Retreatment of treatment failure in CHB and treatment of HBeAg negative patients p
Externí odkaz:
https://doaj.org/article/ed39562c81124164a0d57c6b854b476e
Publikováno v:
International Journal of Hepatology, Vol 2011 (2011)
Patients with decompensated liver cirrhosis have significantly impaired synthetic function. Many proteins involved in the coagulation process are synthesized in the liver. Routinely performed tests of the coagulation are abnormal in patients with dec
Externí odkaz:
https://doaj.org/article/f49ad2b09e124a778fcd99c9101e24cb
Publikováno v:
International Journal of Hepatology, Vol 2011 (2011)
Liver cirrhosis is associated with higher morbidity and reduced survival with appearance of portal hypertension and resultant decompensation. Portal decompression plays a key role in improving survival in these patients. Transjugular intrahepatic por
Externí odkaz:
https://doaj.org/article/b080a5b285234e91bfea39593b357f60
Autor:
Deepak N. Amarapurkar
Publikováno v:
International Journal of Hepatology, Vol 2011 (2011)
Patients with decompensated liver cirrhosis have various serious complications which require multiple drugs for therapeutic or prophylactic use. Majority of the drugs are primarily metabolized and excreted by hepatobiliary system; hence, liver cell n
Externí odkaz:
https://doaj.org/article/655f34e3f30a4d129bfc9c4b98d90d8b
Autor:
Pankaj Puri, Vivek A. Saraswat, Radha K. Dhiman, Anil C. Anand, Subrat K. Acharya, Shivaram P. Singh, Yogesh K. Chawla, Deepak N. Amarapurkar, Ajay Kumar, Anil Arora, Vinod K. Dixit, Abraham Koshy, Ajit Sood, Ajay Duseja, Dharmesh Kapoor, Kaushal Madan, Anshu Srivastava, Ashish Kumar, Manav Wadhawan, Amit Goel, Abhai Verma, null Shalimar, Gaurav Pandey, Rohan Malik, Swastik Agrawal
Publikováno v:
Journal of Clinical and Experimental Hepatology. 6:119-145
India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c90fd72654830ad9ad9086332069e9b
https://doi.org/10.1016/j.jceh.2016.07.001
https://doi.org/10.1016/j.jceh.2016.07.001
Publikováno v:
The Journal of the Association of Physicians of India. 63(11)
Chronic hepatitis B (CHB) infection is a substantial global health problem with highest prevalence observed in the sub-Saharan Africa and East Asia. India lies in the intermediate endemicity zone with prevalence ranging from 0.1% to 11.7%. The predom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4f8fc1e25408fa5268573580ec640c95
https://pubmed.ncbi.nlm.nih.gov/29900711
https://pubmed.ncbi.nlm.nih.gov/29900711